Bevacizumab as a chemoprotectant: reducing oxaliplatin induced hepatic sinusoidal injury

por Mizrahi, Jonathan D., Overman, Michael J.
Publicado 2018

Multi-institutional retrospective analysis of FOLFIRI in patients with advanced biliary tract cancers

por Mizrahi, Jonathan D, Gunchick, Valerie, Mody, Kabir, Xiao, Lianchun, Surapaneni, Phanikeerthi, Shroff, Rachna T, Sahai, Vaibhav
Publicado 2020

Modified gemcitabine plus nab‐paclitaxel regimen in advanced pancreatic ductal adenocarcinoma

por Rogers, Jane E., Mizrahi, Jonathan D., Xiao, Lianchun, Mohindroo, Chirayu, Shroff, Rachna T., Wolff, Robert, Varadhachary, Gauri R., Javle, Milind M., Overman, Michael, Fogelman, David R., Raghav, Kanwal P. S., Pant, Shubham, McAllister, Florencia
Publicado 2020

Antibiotic use influences outcomes in advanced pancreatic adenocarcinoma patients

por Mohindroo, Chirayu, Hasanov, Merve, Rogers, Jane E., Dong, Wenli, Prakash, Laura R., Baydogan, Seyda, Mizrahi, Jonathan D., Overman, Michael J., Varadhachary, Gauri R., Wolff, Robert A., Javle, Milind M., Fogelman, David R., Lotze, Michael T., Kim, Michael P., Katz, Matthew H.G., Pant, Shubham, Tzeng, Ching‐Wei D., McAllister, Florencia
Publicado 2021